| Expression pattern: |
UP |
| Associated gene: |
Nucleolin, hnRNPm |
| Associated microRNA: |
miR-770-5p, miR-370-3p |
| Biological function: |
inhibits cisplatin sensitivity; promotes chemoresistance; inhibits apoptosis and DNA damage after cisplatin |
| Molecular mechanism: |
circTPST2 sponges miR-770-5p and physically interacts with Nucleolin, increasing Nucleolin expression and reducing cisplatin chemosensitivity |
| Biological pathway or process: |
chemoresistance (promotes); apoptosis (inhibits); ceRNA regulation (promotes) |
| Detected method: |
Q
M
|
| Validation methods: |
Microarray; RT-qPCR; Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; Nuclear-Cytoplasmic Fractionation; FISH / smFISH; Clinical Sample Validation; Bioinformatics Analysis; RIP (RNA Immunoprecipitation); RNA Pull-Down; Western Blot; Transfection; CCK8; Annexin V/PI Flow Cytometry; IHC (Immunohistochemistry); Survival Analysis |
| Clinical significance: |
High circTPST2 expression correlated with lower overall survival rates in chemotherapeutic HNSCC patients; potential marker for selecting chemotherapy regimens in HNSCC patients |
| Description: |
circTPST2 (hsa_circ_103188), derived from TPST2, is up-regulated in HNSCC and reduces cisplatin sensitivity. It promotes chemoresistance by sponging miR-770-5p and physically interacting with Nucleolin, increasing Nucleolin expression and suppressing apoptosis/DNA damage under cisplatin treatment. High circTPST2 expression is associated with worse overall survival in chemotherapeutic HNSCC cohorts. |
| Confidence score: |
0.8769 |